Back to today’s briefing

Story perspectives

Study Reveals Mifepristone Risks 22 Times Higher Than FDA Reports

3/25/2026

40 4 Full Breakdown

Summary

Story summary

The Ethics and Public Policy Center reports that serious adverse events from the abortion pill mifepristone occur at about 22 times the rate reported by the U.S. Food and Drug Administration (FDA).
The EPPC analysis also says the mifepristone failure rate is nearly double the FDA's stated rate.
They warn that shipping oversight problems could lead to women receiving compromised drugs.

1 of 1

Story summary

The Ethics and Public Policy Center reports that serious adverse events from the abortion pill mifepristone occur at about 22 times the rate reported by the U.S. Food and Drug Administration (FDA).
The EPPC analysis also says the mifepristone failure rate is nearly double the FDA's stated rate.
They warn that shipping oversight problems could lead to women receiving compromised drugs.